Results 141 to 150 of about 130,425 (315)

Noonan Syndrome Spectrum Disorders Predispose to Systemic Lupus Erythematosus: Case Report and Critical Review of the Literature

American Journal of Medical Genetics Part A, EarlyView.
ABSTRACT RASopathies are clinically overlapping neurodevelopmental syndromes resulting from germline mutations in genes involved in the rat sarcoma/mitogen‐activated protein kinases (RAS/MAPK) pathway. Historically, RASopathies have been described by clinical phenotypes, such as Noonan syndrome and Neurofibromatosis type I.
Anastasia‐Vasiliki Madenidou, Gillian I. Rice, James O'Sullivan, Ben Parker, Ian N. Bruce, Emma Burkitt‐Wright, Tracy A. Briggs   +6 more
wiley   +1 more source

Contemporary Pastoral Activities For the Sake of Humanity, And Peace. Report of the Chaplain of the President of the Republic of Poland

The Person and the Challenges. The Journal of Theology, Education, Canon Law and Social Studies Inspired by Pope John Paul II
Zbigniew Kras
doaj   +1 more source

Supp. Table 3 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in <i>KRAS</i>-Mutant Lung Adenocarcinoma

, 2023
Antonio Calles, Lynette M. Sholl, Scott J. Rodig, Ashley K. Pelton, Jason L. Hornick, Mohit Butaney, Christine Lydon, Suzanne E. Dahlberg, Geoffrey R. Oxnard, David M. Jackman, Pasi A. Jänne   +10 more
openalex   +1 more source

Insights into organelle forming RNAs: Diversity, functions and future perspectives

Animal Models and Experimental Medicine, EarlyView.
RNA molecules play crucial roles in the formation and maintenance of cellular structures and organelles. These ‘organelle formation RNAs’ include ribosomal RNAs, paraspeckle‐forming RNAs, nuclear speckle‐forming RNAs, nucleolus‐forming RNAs, and cytoskeleton‐forming RNA.
Meng Gong, Xiangting Wang, Xiaolin Liang
wiley   +1 more source

Supplementary Figure Legend from Rb Loss and <i>KRAS</i> Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study

, 2023
Susumu Hijioka, Waki Hosoda, Keitaro Matsuo, Makoto Ueno, Masayuki Furukawa, Hideyuki Yoshitomi, Noritoshi Kobayashi, Masafumi Ikeda, Tetsuhide Ito, Shoji Nakamori, Hiroshi Ishii, Yuzo Kodama, Chigusa Morizane, Takuji Okusaka, Hiroaki Yanagimoto, Kenji Notohara, Hiroki Taguchi, Masayuki Kitano, Kei Yane, Hiroyuki Maguchi, Yoshiaki Tsuchiya, Izumi Komoto, Hiroki Tanaka, Akihito Tsuji, Syunpei Hashigo, Yoshiaki Kawaguchi, Tetsuya Mine, Atsushi Kanno, Go Murohisa, Katsuyuki Miyabe, Tadayuki Takagi, Nobutaka Matayoshi, Tsukasa Yoshida, Kazuo Hara, Masayuki Imamura, Junji Furuse, Yasushi Yatabe, Nobumasa Mizuno   +37 more
openalex   +1 more source

Characterization of inflammatory pseudotumors in a large animal model of liver cancer

Animal Models and Experimental Medicine, EarlyView.
CT images in arterial and portal venous phases of liver lesions in Oncopig. Abstract Background The development of relevant and robust large animal models of hepatocellular carcinoma is needed to test new therapeutic strategies for this disease. Transgenic approaches hold promise in addressing this complex problem. One such model, the Oncopig, has been
Erik N. K. Cressman, Samantha Hicks, Natalie W. Fowlkes, Danielle L. Stolley, Maria Sophia Stenkamp   +4 more
wiley   +1 more source

KRAS Inhibition in Pancreatic Ductal Adenocarcinoma. [PDF]

J Clin Med
Pradeep R, Isbeih NJ, Abraham FF, Noori E, Yeung ZP, Kundranda MN.   +5 more
europepmc   +1 more source

Data from Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <i>KRAS</i> Metastatic Colorectal Cancer

, 2023
Eric Van Cutsem, Cathy Eng, Elżbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, И. И. Давиденко, Joe Stephenson, Élena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero   +18 more
openalex   +1 more source

Trametinib in Adults with Neurofibromatosis Type 1‐Related Symptomatic Plexiform Neurofibromas

Annals of Neurology, EarlyView.
Objective Mitogen‐activated protein kinase kinase inhibitors have shown promising results in treatment of plexiform neurofibromas in neurofibromatosis type 1 patients, but data in adults are limited. The aim of this phase 2 study was to investigate the efficacy and safety of trametinib in adults with neurofibromatosis type 1.
D. Christine Noordhoek, David F. Hanff, Pim J. French, Sarah A. van Dijk, Erik A.C. Wiemer, Olivier C. Manintveld, Martin J. van den Bent, Walter Taal   +7 more
wiley   +1 more source

Unraveling the Impact of KRAS Accessory Proteins on Oncogenic Signaling Pathways. [PDF]

Cells
Garg V, Hofmann RNHM, Saleem M, Mirzaiebadizi A, Hashemi GS, Hameed T, Jooyeh B, Pudewell S, Mehrabipour M, Mosaddeghzadeh N, Piekorz RP, Ahmadian MR.   +11 more
europepmc   +1 more source